A Randomized, Double-Blinded, Placebo-Controlled, Phase 2 Study With and Without Enzastaurin in Combination With Docetaxel and Prednisone, Followed By Enzastaurin Maintenance as First-Line Treatment in Hormone Refractory Metastatic Prostate Cancer Patients
A Randomized, Double-Blinded, Placebo-Controlled, Phase 2 Study With and Without Enzastaurin in Combination With Docetaxel and Prednisone, Followed By Enzastaurin Maintenance as First-Line Treatment in Hormone Refractory Metastatic Prostate Cancer Patients
The purpose of the study is to compare the response rates for prostate cancer patients taking chemotherapy plus enzastaurin versus chemotherapy plus placebo.
Inclusion Criteria:
Exclusion Criteria:
Fullerton, California 92835, United States
Los Angeles, California 90093, United States
Northridge, California 91328, United States
Redondo Beach, California 90277, United States
Santa Barbara, California 93105, United States
Santa Maria, California 93454, United States
Miami, Florida 33179, United States
Chicago, Illinois 60637, United States
Harvey, Illinois 60426, United States
Minneapolis, Minnesota 55404, United States
Columbia, Missouri 65201, United States
Kansas City, Missouri 64128, United States
Billings, Montana 59101, United States
Henderson, Nevada 89169, United States
Las Cruces, New Mexico 88011, United States
Raleigh, North Carolina 27607, United States
Cleveland, Ohio 44195, United States
Memphis, Tennessee 38138, United States
Dallas, Texas 75246, United States
The Woodlands, Texas 77380, United States
Newport News, Virginia 23606, United States
Vancouver, Washington 98684, United States
Erlangen, 91054, Germany
Hamburg, 22399, Germany
Mannheim, 68163, Germany
Como, 22100, Italy
Orbassano, 10043, Italy